BHCN Stock Chart & Stats
$83.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$83.00 - $152.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)353.00
Market Cap
$28.94B
Enterprise Value$31.36K
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$20.80B
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Jul 29, 2026EPS Estimate
17.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding373,475,650
10 Day Avg. Volume460
30 Day Avg. Volume353
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BHCN FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $83.00 and its highest was $152.00 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $28.94B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Jul 29, 2026 which is in 4 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Apr 29, 2026. The company reported $13.213 earnings per share for the quarter, beating the consensus estimate of $11.447 by $1.767.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies does not currently pay dividends.
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 17.34.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 373,475,650 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $13.213 in its last earnings report, beating expectations of $11.447. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in MX:BHCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.28%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.